pharmaceuticals
publication date
Payer
Medicare Drug Plans Are Getting Better Next Year. Some Will Also Cost More.
KFF found that 'many insurers are increasing premiums' and that large insurers including UnitedHealthcare and Aetna may reduced the number...
Pharma
Helene and CVS Land Double Whammy for 25K Patients Who Survive on IV Nutrition
Patients who rely on parenteral nutrition have a variety of conditions that render them unable to digest food.
CEO
Implications of port strike: Updated
The strike at 36 ports handling one-half of U.S. ocean imports could cost the economy $5 billion a day and...
CEO
Cardinal Health to Acquire Integrated Oncology Network in 'Cancer Care Arms Race'
The pharmaceutical distributor giant is strengthening its oncology business to compete with its peers.
CMO
How Medication Management Can Cut Admissions, ICU Stays
CMOs need their physicians to be addressing prescription overload.
Innovation
Antibiotic Prescriptions in Virtual Care Can Be a Cause for Concern
A new study by the Cleveland Clinic finds that clinicians tend to prescribe more antibiotics in virtual care visits than...
Payer
Contributed Content: 2 Alternatives to Ineffective Prescription Drug Rebates
Prescription drug rebates were once a good idea. Not any more.
Innovation
An AI Cure for the Stuffy Nose?
The latest in digital therapeutics features a new device that uses Ai to scan a patient?s sinuses and create an...
CFO
3 Areas Where CFOs Are Laser Focused
"We are not going to leave dollars on the table," CFOs say.
Innovation
Hospitals Take to the Air to Improve Home-Based Care
As health systems shift more care services to the patient's home, they're looking at drones to solve key supply chain...
Pharma
Beacon Therapeutics CEO Puts Patients First in Mission to Prevent Blindness
David Fellows is guided by listening to patients and their families as they prepare for one of life?s worst moments--a...
Pharma
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The heavier dosage allows AmGen to protect 75% of its revenue from the drug, which earned $200 million last year.